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Abstract Class I ADP-ribosylation factors (ARFs) are essen-
tial for coatomer and clathrin coat assembly and vesicular
transport in the Golgi apparatus. However, little is known about
the in vivo regulation of ARF actions. Recently we cloned
arfaptin 1, a 39 kDa protein that binds active, GTPQS-liganded
ARF and translocates with it to Golgi membranes. Here we show
that phorbol ester-stimulated phospholipase D (PLD) activity is
inhibited in arfaptin 1-overexpressing NIH 3T3 cells and that
arfaptin 1 inhibits ARF activation of Golgi-associated PLD.
Since PLD activity is thought to play a role in regulating
vesicular transport in the secretory pathway, we determined the
rate of glycosylation of vesicular stomatitis virus glycoprotein as
a measure of protein transport from the endoplasmic reticulum
through the Golgi apparatus. Arfaptin 1 overexpression was
found to decrease the rate of this reaction approximately two-
fold. These data suggest that arfaptin 1 is a regulator of ARF
action in the Golgi apparatus.
1. Introduction
The important role of ADP-ribosylation factor (ARF) in
recruitment of COPI (coatomer) and clathrin coat proteins
to the Golgi apparatus is well established [1^5]. Inhibition
of ARF with brefeldin A (BFA), a fungal metabolite that
inhibits guanine nucleotide exchange on ARF, totally blocks
vesicle formation and secretion and leads to collapse of the
Golgi very rapidly after addition [4,6]. ARF is also a regulator
of phospholipase D (PLD) [7^9]. Furthermore, recent studies
have associated the formation of phosphatidic acid (PA) by
PLD with vesicle budding on the Golgi [10^13]. For example,
addition of PLD stimulates secretory vesicle budding from
Golgi membranes [12] and induces coatomer binding to Golgi
membranes [10], whereas 1-butanol and ethanol, inhibitors of
PLD-catalyzed PA formation, impair this [12]. Furthermore,
in cells expressing high PLD activity, the requirement for
ARF during coat assembly on Golgi membranes is replaced
[10]. These results suggest that PLD mediates some of the
e¡ects of ARF on the Golgi.
Arfaptin 1 is a class I ARF-binding protein [14] that was
shown to associate with the GTPQS-bound form of ARF-1
and then to interact with Golgi membranes [14]. In vitro ar-
faptin 1 inhibits ARF-dependent PLD activation [15]. In a
recent study we showed that ARF and PLD are involved in
PKC stimulation of matrix metalloproteinase-9 (MMP-9) se-
cretion from HT 1080 cells (B.-T. Williger, W.-T. Ho, S.
Gharacholou and J.H. Exton, submitted). In the present
study, we investigated the e¡ects of arfaptin 1 overexpression
in NIH 3T3 cells. In cells stably transfected with arfaptin 1,
we found that PLD activity was greatly inhibited compared to
control cells. Furthermore, transport of vesicular stomatitis
virus glycoprotein (VSV-G) from the endoplasmic reticulum
(ER) through the Golgi apparatus was attenuated in cells
overexpressing arfaptin 1. We also show that arfaptin 1 can
inhibit the stimulation of Golgi-associated PLD activity by
ARF. These results suggest that arfaptin 1 and PLD regulate
vesicular transport in the secretory pathway.
2. Materials and methods
2.1. Materials
Essentially fatty acid-free bovine serum albumin (BSA), Tween 20,
sodium dodecyl sulfate and phorbol 12-myristate 13-acetate (PMA)
were products of Sigma. All organic solvents were of ¢ne grade and
obtained from Fisher. Horseradish peroxidase-labeled goat anti-rabbit
antiserum was purchased from Vector. Enhanced chemiluminescence
kit was purchased from Amersham. Non-fat dry milk was obtained
from Bio-Rad. Lipofectamine, Dulbecco’s modi¢ed Eagle’s medium
(DMEM), fetal calf serum (FCS) and all other supplements for
growth media were purchased from Gibco BRL. All radioactive ma-
terials were products of NEN/Dupont. Protogel (acrylamide:bisacryl-
amide solution) was purchased from National Diagnostics. pTK-Hyg
and pTRE plasmids were obtained from Clontech. GST-arfaptin 1
was puri¢ed from pGEX-2T/arfaptin 1-transformed Escherichia coli
(DH5K) as described before [16], except that before the a⁄nity chro-
matography the bacterial lysate was dialyzed against phosphate-buf-
fered saline overnight at 4‡C. Recombinant myrARF3 was puri¢ed as
previously described [14].
2.2. Cell culture and production of arfaptin 1-overexpressing cells
All cells were maintained in DMEM, 10% FCS, 10 U/ml penicillin
and 10 Wg/ml streptomycin. Before fractionation or PLD assay the
cells were serum-deprived for 18 h in DMEM, 0.1% BSA. For PLD
assays, 1 WCi/ml [3H]myristic acid was included. Arfaptin 1-overex-
pressing NIH 3T3 cells were produced by cotransfection with pTK-
Hyg and either arfaptin 1 in the pTRE vector (Clontech) or pTRE
alone as a control using lipofectamine according to the manufacturer’s
instructions. Selection was carried out in hygromycin B for 6 weeks.
2.3. In vivo and in vitro PLD assays
Serum-deprived and labeled cells were washed with DMEM, 0.1%
BSA. Following 20 min preincubation in DMEM, 0.1% BSA, 0.3%
1-butanol, the cells were stimulated with PMA at the concentrations
described in the ¢gure legends. After 20 min, the cells were washed
with PBS (2.68 mM KCl, 1.47 mM KH2PO4, 8.05 mM Na2PO4,
137 mM NaCl) including 0.1% BSA, scraped with 1 ml ice-cold
CH3OH and transferred into glass tubes. CHCl3 and 0.1 N HCl
were then added to a ¢nal ratio of 1:1:1. The lipid-containing lower
phase was collected, dried and dissolved in 30 Wl CH3OH, CHCl3
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(1:1). The sample was loaded on a thin layer chromatography plate
which was developed in the lower phase of H2O, ethylacetate, acidic
acid and iso-octane (100:110:20:50 respectively). Tritiated phosphati-
dylbutanol (PtdBut) was measured after scraping the band corre-
sponding to a PtdBut standard (Avanti Polar Lipids). In vitro PLD
assays were done as described [7] with the exception that before the
assay GST-arfaptin 1 was incubated with myrARF3 in reaction bu¡er
for 15 min on ice and then 1% butanol, phospholipid vesicle substrate
and 50 Wg Golgi-enriched membranes were added.
2.4. Vesicular stomatitis virus glycoprotein tra⁄cking assay
Infection of cells with VSV, pulse-chase labeling of VSV-G, and
digestion of VSV-G with endoglycosidase H (Endo H) were carried
out as described [17]. VSV-G was visualized by phosphorimaging.
Exposures were chosen with maximum intensity (100% black) between
102 and 103. Minimum intensity (0% black) was set to 1/100 of this
value and intensities between were linearly assigned gray scale values
from 0 to 100%.
2.5. Cell fractionation
Serum-deprived cells were washed twice with phosphate-bu¡ered
saline and scraped with fractionation bu¡er (100 mM KCl, 5 mM
NaCl, 1 M MgCl2 and 0.5 mM EDTA in 50 mM HEPES pH 7.2).
The cells were broken by 30 min cavitation under 350 psi nitrogen and
40 s sonication. Unbroken cells and large debris were removed by
15 min centrifugation at 750Ug. The recovered supernatant was cen-
trifuged at 12 600Ug for 20 min to remove cell membranes. Golgi-
enriched membranes were separated from the cytosol by a ¢nal cen-
trifugation at 38 600Ug for 75 min and resuspended in fractionation
bu¡er. The supernatant was used as a source for cytosol.
3. Results
3.1. Overexpression of arfaptin 1 in NIH 3T3 cells
Arfaptin 1 overexpression inhibits secretion of MMP-9 in
HT 1080 cells (B.-T. Williger, W.-T. Ho, S. Gharacholou and
J.H. Exton, submitted). In this study we investigated the role
of arfaptin 1 in NIH 3T3 cells. The cells were cotransfected
with pTK-Hyr and either empty pTRE or pTRE-arfaptin 1 as
described in Section 2. Selection was maintained for 6 weeks
in hygromycin B and then expression of arfaptin 1 was as-
sayed. Serum-deprived cells were fractionated and cytosol and
Golgi-enriched membranes were separated by SDS polyacryl-
amide gel electrophoresis. The proteins were immunoblotted
with anti-arfaptin 1. Fig. 1 shows that expression of arfaptin 1
was signi¢cantly increased in both cytosol and Golgi mem-
branes from cells transfected with pTRE-arfaptin 1 versus
cells transfected with empty vector (pTRE).
3.2. Inhibition of PMA stimulation of PLD in arfaptin
1-overexpressing cells
As noted above, ARF has been shown to activate PLD and
has been implicated in the regulation of Golgi function. Pre-
vious ¢ndings have shown that arfaptin 1 inhibits PLD activ-
ity in vitro [15] and in HT 1080 cells (B.-T. Williger, W.-T.
Ho, S. Gharacholou and J.H. Exton, submitted). In light of
these data, we compared PLD activity in arfaptin 1-overex-
pressing and control cells stimulated with PMA. Cells were
labeled overnight with [3H]myristic acid, treated with 1-buta-
nol for 20 min, and stimulated with various concentrations of
PMA. PLD activity measured by the formation of [3H]PtdBut
was decreased in the cells overexpressing arfaptin 1 (Fig. 2).
3.3. Arfaptin 1 overexpression attenuates VSV-G tra⁄cking
It has previously been shown that inhibition of ARF acti-
vation by BFA impairs tra⁄cking through the Golgi appara-
tus and secretion [6]. Furthermore, it has been shown that this
treatment leads to coatomer redistribution from the Golgi to
the cytosol [2,4], suggesting that the impairment of tra⁄cking
and secretion is due to inhibition of vesicle formation. We
therefore studied vesicle tra⁄cking in arfaptin 1-overexpress-
ing NIH 3T3 cells. For this purpose, we measured the trans-
port of VSV-G from the ER through the Golgi apparatus in
arfaptin 1-overexpressing cells compared with control cells.
We used a pulse-chase protocol to measure the kinetics of
the disappearance of the ER- and early Golgi-localized
(Endo H) sensitive form of VSV-G [17]. Overexpression of
arfaptin 1 slowed the glycosylation of VSV-G as it is trans-
ported from the ER through the Golgi apparatus (Fig. 3A).
This is shown quantitatively in Fig. 3B by determining the
amount of radioactivity in the Endo H-sensitive form of
VSV-G after di¡erent chase times.
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Fig. 1. Expression of arfaptin 1 in transfected cells. NIH cells were
transfected with pTK-Hyg and pTRE or pTRE containing arfaptin
1. After selection for 6 weeks, the cells were serum-deprived for 18
h and then fractionated as described in Section 2. Cytosol or Golgi-
enriched membranes (15 Wg) were separated on 10% polyacrylamide
gels and were immunobltoted with rabbit anti-arfaptin 1 polyclonal
antibodies. Immunoreactive bands were visualized after incubation
with horseradish peroxidase-labeled goat anti-rabbit serum and re-
agent (C, cystosol; G, Golgi-enriched membrane).
Fig. 2. E¡ects of arfaptin 1 on PLD activity in vivo. [3H]Myristic
acid-labeled control cells (E) and arfaptin 1-overexpressing cells (F)
were preincubated for 20 min with 0.3% 1-butanol in DMEM, 0.1%
BSA and then stimulated with the indicated concentrations of PMA
for 20 min. PLD activity was measured by the production of
[3H]PtdBut as described in Section 2. Data are means þ S.E.M. of
three experiments.
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3.4. Arfaptin 1 inhibits ARF-stimulated PLD activity in Golgi
membranes
Although arfaptin 1 has been shown to inhibit ARF-stimu-
lated PLD partially puri¢ed from rat brain membranes [15],
we thought that it was important to demonstrate this for the
PLD activity associated with Golgi membranes. Golgi-en-
riched membranes were prepared from HT-1080 cells as de-
scribed in Section 2. Fig. 4 shows that myristoylated ARF3
produced a 3-fold stimulation of PLD activity in the presence
of guanosine 5P,3-O-(thio)triphosphate (GTPQS). Increasing
concentrations of arfaptin 1 produced complete inhibition of
the e¡ect of ARF3.
4. Discussion
The present ¢ndings support previous observations that ar-
faptin 1 is an inhibitor of ARF actions in vitro including PLD
activity (Fig. 4) [15]. Nevertheless, the intracellular role of
arfaptin 1 is unclear. In this study we report that overexpres-
sion of arfaptin 1 in NIH 3T3 cells inhibited PMA-stimulated
PLD activity. This result suggests that ARF could be involved
in the action of PMA on PLD. This could arise because PMA
modulates ARF activation or activity. Alternatively, the e¡ect
could be due to the demonstrated synergistic interaction be-
tween PKC and ARF in the regulation of PLD [18,19]. The
idea that PKC could modulate ARF activation or activity is
an attractive one, but clearly needs more support.
The other major observation was that VSV-G tra⁄cking
from the ER and through the Golgi was inhibited in arfaptin
1-overexpressing cells. This observation is supported by an-
other study showing that arfaptin 1 overexpression results in
inhibition of MMP-9 secretion (B.-T. Williger, W.-T. Ho, S.
Gharacholou and J.H. Exton, submitted). These ¢ndings in-
dicate that arfaptin 1 has inhibitory activity in vivo consistent
with its in vitro e¡ects. The e¡ects of arfaptin 1 on VSV-G
tra⁄cking and on MMP-9 secretin were not as great as those
of BFA, which produced complete inhibition [6] (B.-T. Wil-
liger, W.-T. Ho, S. Gharacholou and J.H. Exton, submitted).
This probably re£ects the fact that whereas fully inhibitory
concentrations of BFA could be produced by addition, com-
pletely inhibitory concentrations of arfaptin 1 could not be
achieved by expression.
An intriguing possibility is that the inhibitory action of
arfaptin 1 on Golgi function is due in part to its inhibition
of ARF-mediated activation of PLD. As noted above, the
inhibition of PLD activity has been previously demonstrated
for partially puri¢ed brain PLD in vitro [15] and is also shown
for Golgi-associated PLD in the present study (Fig. 4). Inhib-
ition of PMA stimulation of PLD is also observed in vivo
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Fig. 3. E¡ects of arfaptin 1 on VSV-G tra⁄cking in cells. A: Con-
trol cells (E) and arfaptin 1-overexpressing cells (F) were infected
with VSV. After incubation for 3.75 h, the cells were pulsed with
1 mCi/ml of [35S]methionine/cysteine for 5 min and the Endo H-re-
sistant VSV-G form was chased by sampling the cells at the indi-
cated times. Endo H-resistant and -sensitive forms of VSV-G, meas-
ured as described in [17] are indicated. B: VSV-G tra⁄cking was
calculated after measuring band densities. Data presented as the rel-
ative disappearance of the Endo H-resistant form.
Fig. 4. E¡ects of ARF and arfaptin 1 on Golgi-associated PLD ac-
tivity. Golgi-enriched membranes (50 Wg) were prepared from HT
1080 cells as described in Section 2. They were incubated with
0.3 WM myristoylated ARF3 and 0.83 mM GTPQS with or without
the indicated concentrations of GST-arfaptin 1. PLD activity was
assayed in vitro using [3H]palmitoyl phosphatidylcholine as de-
scribed in [7].
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(Fig. 2) (B.-T. Williger, W.-T. Ho, S. Gharacholou and J.H.
Exton, submitted), although the basis for the latter e¡ect is
unclear (see above). There is also evidence that PLD plays a
role in PMA-stimulated secretion since this inhibited by
1-propanol through the transphosphatidylation reaction to a
much greater extent than 2-propanol [20]. In view of the evi-
dence that ARF regulates PLD activity in Golgi membranes
[10,12,21] and that PLD could play a role in Golgi function
[10^13] and secretion [20], it seems reasonable to propose that
arfaptin 1 exerts part of its e¡ect on vesicle tra⁄cking and
secretion via inhibition of PLD activity.
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